Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 6/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883864 | 0.83 | DRD2 (0.71) | DRD2TBXA2RGAAPTGDR2MEN1 | |
| SCHEMBL2881289 | 0.81 | DRD2 (0.68) | DRD2TBXA2RGAANPC1RAB9A | |
| SCHEMBL28238574 | 0.80 | LMNA (0.68) | MAPK1PKMGAANPC1RAB9A | |
| SCHEMBL2952525 | 0.78 | PKM (0.58) | DRD2TBXA2RPKMGAANPC1 | |
| SCHEMBL23997462 | 0.76 | DRD2 (0.75) | DRD2TBXA2RPTGDR2TP53 | |
| SCHEMBL30336823 | 0.76 | DRD2 (0.75) | DRD2TBXA2RPTGDR2TP53 | |
| SCHEMBL15643422 | 0.76 | DRD2 (0.77) | DRD2TBXA2RPTGDR2TP53 | |
| SCHEMBL9201172 | 0.75 | DRD2 (0.78) | DRD2TBXA2RTP53 | |
| SCHEMBL3668391 | 0.74 | HDAC1 (0.73) | DRD2TBXA2RRAB9APTGDR2TP53 | |
| SCHEMBL13085873 | 0.74 | DRD2 (0.58) | DRD2TBXA2RPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820825-B2 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-10-26 | — | — | US | disclosed |
| CN-101426778-A | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH CORP (US) | 2009-05-06 | — | — | CN | disclosed |
| EP-1994022-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007108936-A2 | N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | DRD2 300/4885TBXA2R 434/4885MAPK1 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.